Secretaria de Ciência, Tecnologia e Insumos Estratégicos/MS - FTN

Size: px
Start display at page:

Download "Secretaria de Ciência, Tecnologia e Insumos Estratégicos/MS - FTN"

Transcription

1 SEÇÃO A - Referências 1. World Health Organization. WHO model formulary Geneva: WHO; Available from: <http://mednet3.who.int/emlib/modelformulary/modelformulary.asp>. 2. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 54 th. ed. London: BMJ Publishing Group and APS Publishing; Available from: <http://www.bnf.org>. 3. British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London: BMJ Publishing Group, RPS Publishing and RCPCH Publications; Klasco RK, editor. USP DI Drug Information for Health Care Professional [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX; [Cited 2006 Oct 5]. Available from: <http://www.periodicos.capes.gov. br>. 5. Klasco RK, editor. DRUGDEX System [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX; [Cited 2006 Oct 5]. Available form: <http://www.periodicos.capes.gov.br>. 6. Klasco RK, editor. Martindale: the extra pharmacopoeia. [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX; [Cited 2006 Oct 5]. Available from: <http://www.periodicos.capes.gov.br>. 7. Escola Nacional de Saúde Pública. Núcleo de Assistência Farmacêutica. Fundamentos farmacológicos-clínicos dos medicamentos de uso corrente Rio de Janeiro: ENSP; [CD-rom] 8. Wannmacher L, Bermudez JAZ, Reis, ALA, Osorio-de-Castro CGS, Pepe VLE, Luiza VL, Bonfim J R.A, Silver LD, Marín N. Formulário Terapêutico Nacional. Rio de Janeiro : ENSP; [mimeo] 9. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook Hudson: Lexi-Comp; Tatro DS, editor. Drug Interaction Facts 2005: the authority on drug interactions. St. Louis: Facts & Comparisons; Briggs GG, Freeman RK, Yafee SJ. Drugs in pregnancy and lactation. 6 th. ed. Philadelphia: Williams & Wilkins; Dukes MNG, Aronson JK, editors. Meyler s side effects of drugs. 14 th. ed. Amsterdam: Elsevier; McEvoy GK, editor. AHFS Drug information. Bethesda, MD: ASHP; Evers AS, Crowder CM, Balser JR. General anesthetics. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill; 2006: Moraes RS, Fuchs FD. Oxigênio. In: Fuchs FD, Wannmacher L, Ferreira MBC, editores. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Westrin P. Intravenous anaesthesia in paediatric patients. Acta Anaesthesiol Scand 1999; 43(suppl 114): McQueen AL, Baroletti AS. Adjuvant ketamine analgesia for the management of cancer pain. Ann Pharmacother 2002; 36: Dodds C. General anaesthesia. Practical recommendations and recent advances. Drugs 1999; 58(3): Nakayama S, Furukawa H, Yanai H. Propofol reduces the incidence of emergence agitation in preschool-aged children as well as in school-aged children: a comparison with sevoflurane. J Anesth 2007; 21(1): Bloomstone JA. Propofol: A Novel Treatment for Breaking Migraine Headache. Am Soc Anesth 2007; 106 (2): [Letter] 21. Kelly DF, Goodale DB, Williams J, Herr DL, Chappell ET, Rosner MJ et al. Propofol in the treatment of moderate and severe head injury: a randomized, prospective doubleblind pilot trial. J Neurosurg 1999; 90: Fragen RJ, Avram MJ. Barbiturates. In: Miller RD, ed. Anesthesia. 5 th. ed. Philadelphia: Churchill Livingstone; 2000:

2 23. Walker K J, Smith A F, Pittaway A J. Premedication for anxiety in adult day surgery (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 24. Reves JG, Glass PSA, Lubarsky DA. Nonbarbiturate intravenous anesthetics. In: Miller RD, ed. Anesthesia. 5 th. ed. Philadelphia: Churchill Livingstone; 2000: Catterall WA, Mackie K. Local anesthetics. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill; 2006: Requa-Clark BS. Local anesthetics. In: Requa-Clark B. Applied pharmacology for the dental hygienist. 4 th. ed. St. Louis: Mosby; 2000: Strichartz GR, Berde CB. Local anesthetics. In: Miller RD, ed. Miller s Anesthesia. 6 th. ed. Philadelphia: Elsevier; Churchill Livingstone; 2005: Naftalin LW, Yagiela JA. Vasoconstritors: indications and precautions. Dent Clin N Am 2002; 46: Neal JM. Effects of epinephrine in local anesthetics on the central and peripheral nervous systems: neurotoxicity and neural blood flow. Reg Anesth Pain Med 2003; 28(2): Berde CB, Strichartz GR. Local anesthetics. In: Miller RD, ed. Anesthesia. 5 th. ed. Philadelphia: Churchill Livingstone; 2000: Hodgson PS, Neal JM, Pollock JE, Liu SS. The neurotoxicity of drugs given intrathecally. Anesth Analg 1999; 88: Zaric D, Christiansen C, Pace NL, Punjasawadwong Y. Transient neurologic symptoms (TNS) following spinal anaesthesia with lidocaine versus other local anaesthetics (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 33. Ferreira MBC. Anestésicos locais. In: Fuchs FD, Wannmacher L, Ferreira MBC eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Savarese JJ, Caldwell JE, Lien CA, Miller RD. Pharmacology of muscle relaxants and their antagonists. In: Miller RD, ed. Anesthesia. 5 th. ed. Philadelphia: Churchill Livingstone; 2000: Meakin GH. Muscle relaxants in paediatric day case surgery. Eur J Anaesthesiol 2001; 18 (Suppl 23): Sparr HJ. Choice of the muscle relaxant for rapid-sequence induction. Eur J Anaesthesiol 2001; 18 (suppl 23): Perry J, Lee J, Wells G. Rocuronium versus succinylcholine for rapid sequence induction intubation (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 38. Ferreira MBC. Relaxantes musculares periféricos. In: Fuchs FD, Wannmacher L, Ferreira MBC (eds.). Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill; 2006: Khuenl-Brady KS, Reitstatter B, Schlager A, Schreithofer D, Luger T, Seyr M, et al. Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg 1994; 78: Murray MJ, Coursin DB, Scuderi PE, Kamath G, Prough DS, Howard DM, Abou- Donia MA. Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents. Crit Care Med 1995; 23: Gales BJ, Gales MA.Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother 2007; 41(2): Cools F, Offringa M. Neuromuscular paralysis for newborn infants receiving mechanical ventilation (Cochrane Review). In: The Cochrane Library, Issue 3, Oxford: Update

3 44. Oxford league table of analgesics in acute pain. Oxford: Bandolier, [Cited 2007 Jul 06]. Available from: <http://www.jr2.ox.ac.uk/bandolier/booth/painpag/acutrev/ Analgesics/Leagtab.html>. 45. Wannmacher L. Analgésicos não-opióides. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2007: WANNMACHER, Lenita ; FERREIRA, M. B. C.. Febre: mitos que determinam condutas. Uso Racional de Medicamentos Temas Selecionados, Brasília, 2004; 1(9): Meremikwu M, Oyo-Ita A. Physical methods for treating fever in children (Cochrane Review). In: The Cochrane Library, Issue 1; Oxford: Update 48. Eiland LS, Berger BA. Pediatric OTC medications. Part III: fever. US Pharmacist 2003; 28 (12). [Cited 2007 Jun 17]. Available from: <http://www.unb.br/fs/ farmacologiaclinica/analgesicosantipireticosetratamentodaenxaquecalenita.pdf>. 49. Mayoral CE, Marino RV, Rosenfeld W, Greensher J. Alternating antipyretics: is this an alternative? Pediatrics 2000; 105: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications. BNF for children London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications, 2005: Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther 2000; 7: Burke A, Smyth E, Fitzgerald GA. Analgesic-antipyretic agents: pharmacotherapy of gout. In: Brunton LL, Lazo JS, Parker KL eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill, 2006: Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol(acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 2000; 7 (2): Spigset O, Hagg S. Analgesics and breast-feeding: safety considerations. Paediatr Drugs 2000; 2: Tréluyer JM, Tonnelier S, d Athis P, Leclerc B, Jolivet-Landron I, Pons G. Antipyretic efficacy of an initial 30 mg/kg loading dose of acetaminophen versus a 15 mg/kg maintenance dose. Pediatrics 2001; 108: Averbuch M, Katzper M. Severity of baseline pain and degree of analgesia in the third molar post-extraction dental pain model. Anesth Analg 2003; 97 (1): Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: Bjornsson GA, Haanaes HR, Skoglund LA. A randomized, double-blind crossover trial of paracetamol 1000 mg four times daily vs ibuprofen 600 mg: effect on swelling and other postoperative events after third molar surgery. Br J Clin Pharmacol 2003; 55 (4): Wahba H. The antipyretic effect of ibuprofen and acetaminophen in children. Pharmacotherapy 2004; 24: Wannmacher L. Paracetamol versus Dipirona: como mensurar o risco? In: OPAS. Uso racional de medicamentos Temas Selecionados, Brasília, 2005;2(5): Edwards JE, Meseguer F, Faura CC, Moore RA, McQuay HJ. Single dose dipyrone for acute postoperative pain (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 62. Edwards JE, Meseguer F, Faura C, Moore RA, McQuay HJ. Single dose dipyrone for acute renal colic pain (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 63. Wong A, Sibbald A, Ferrero F, Plager M, Santolaya ME, Escobar AM, Campos S, Barragan S, De Leon Gonzalez M, Kesselring GL; Fever Pediatric Study Group. Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study. Clin Pediatr, (Phila) 2001; 40 (6):

4 64. Gozzoli V, Treggiari MM, Kleger GR, Roux-Lombard P, Fathi M, Pichard C, Romand JA. Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response. Intensive Care Med 2004; 30: Oborilova A, Mayer J, Pospisil Z, Koristek Z. Symptomatic intravenous antipyretic therapy: efficacy of metamizol, diclofenac, and propacetamol. J Pain Symptom Manage 2002; 24: Ibanez L, Vidal X, Ballarin E, Laporte JR. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 2005; 60(11): Schonhofer PS. Dipyrone (Metamizol): Restored to Good Reputate? Internistiche Praxis 1999; 39: Availale from: <http://www.sobravime.org.br/disc_dipirona. html>. 68. Sharpe CR, Franco EL. Use of dipyrone during pregnancy and risk of Wilms tumor. Brazilian Wilms Tumor Study Group. Epidemiology 1996; 7: Bar-Oz B, Clementi M, Di Giantonio E, Greenberg R, Beer M, Merlob P, et al. Metamizol (dipyrone, optalgin) in pregnancy, is it safe? A prospective comparative study. Eur J Obstet Gynecol Reprod Biol 2005; 119 (2): BRASIL. Agência Nacional de Vigilância Sanitária. Bulário Eletrônico da Anvisa. [Citado 2007 jul. 11]. Disponível em: <http://bulario.bvs.br>. 71. Gutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill; 2006: Ferreira MBC, Hidalgo MPL, Caumo W. Analgésicos Opióides. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2007: Maxwell SRJ, Bateman DN. Choice of opioid analgesics in postoperative care. Lancet 2007; 369 (9578): [Letter] 74. Kosinski M, Janagap C, Gajria K, Schein J, Freedman J. Pain relief and pain-related sleep disturbance with extended-release tramadol in patients with osteoarthritis. Curr Med Res Opin 2007; Jun 1, 23(7): Moore A, Collins S, Carroll D, McQuay H, Edwards J. Single dose paracetamol (acetaminophen), with and without codeine, for postoperative pain (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 76. Wannmacher L, Ferreira MBC. Enxaqueca: Mal Antigo Com Roupagem Nova. In: OPAS. Uso racional de medicamentos Temas Selecionados, Brasília, 2004;1(8): Goadsby PJ, Lipton RB, Ferrari MD. Drug therapy: migraine current understanding and treatment. New Engl J Med 2002; 346: Morillo LE. Migraine headache. BMJ Clinical Evidence. Web publication date: 01 May 2004 (based on August 2003 search) 79. Tomkins GE, Jackson JL, O Malley PG, Balden E, Santoro JE.Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 2001; 111: Morey SS. Guidelines on migraine: Part 5. Recommendations for specific prophylactic drugs. Am Fam Physician 2000; 62: Eiland LS, Jenkins LS, Durham SH. Pediatric Migraine: pharmacologic agents for prophylaxis. Ann Pharmacother 2007 Jun Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 2000; 160: Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998; 55: Moore A, Mcquay H. Migraine special issue. Bandolier Extra: Evidence-based health care. January 2002: Pharmacological prevention of migraine: to be considered case by case. Prescrire Int 2006; 15 (85): Food and Drug Administration s Pregnancy Category. In: DRUGDEX System [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX;

5 [Cited 2006 Oct 5]. Available form: <http://www.periodicos.capes.gov. br>. 87. UpToDate online [Internet] version Propranolol. In: UpToDate, Rose BD editors, UpToDate, Waltham, MA, [Cited 2007 Dec 8]. Available from: <http://www. utdol.com/utd/content/search.do?search = propranolol&searchoffset = 0&source = MISSPELL>. 88. Miller JM, Zipes DP. Therapy for cardiac arrhythmias. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald s Heart Disease. 7 th. ed. Philadelphia: Elsevier Saunders; 2005: Wannmacher L, Ferreira MBC. Antiinflamatórios não-esteróides. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Silverstein FE, Faich G, Goldstein JL, et al, for the Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs. non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: Bombardier C, Lame L, Reicin A, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002; 325: Garner SE, Fidan DD, Frankish RR, Judd MG, Shea BJ, Towheed TE, Tugwell P, Wells G. Celecoxib for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 94. Las supuestas ventajas de celecoxib y rofecoxib: fraude científico. Butll Groc 2002; 15: Singh D. Merck withdraws arthritis drug worldwide. BMJ 2004; 329: Toxicidad de los inibidores de la COX-2: celecoxib y rofecoxib. Butll Groc 2000; 13: Moore RA, Tramer MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998; 316: Gotzsche PC. Non-steroidal anti-inflammatory drugs. In: BMJ Clinical Evidence. Web publication date: 01 May 2006 (based on December 2006 search) 99. BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications. BNF for children London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications, 2005: Wannmacher L. Inibidores da bomba de prótons: indicações racionais. In: OPAS. Uso Racional de Medicamentos Temas Selecionados, Brasília, 2004;2(1): Wannmacher L. Antiinflamatórios não esteróides. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2007: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain. British National Formulary. 50 th. ed. London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain; September 2005: Edwards JE, Oldman A, Smith L, Collins SL, Carroll D, Wiffen PJ, McQuay HJ, Moore RA. Single dose oral aspirin for acute pain (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 104. Mehta DK, Ryan RSM, Hill S, eds. WHO Model Formulary Geneva: Royal Pharmaceutical Society of Great Britain, Department of Medicines Policy and Standards, WHO; Wannmacher L. Antiinflamatórios. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2007: Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman s the

6 pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill, 2006: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications. BNF for children London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications, 2005: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain. British National Formulary. 50 th. ed. London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain; September 2005: Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 110. McNamara M. Bottoms S. The incidence of respiratory distress syndrome does not increase when preterm delivery occurs greater than 7 days after steroid administration. Aust NZ J Obstet Gynaecol 1998; 38: McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since JAMA 1997; 278: Davis PG, Henderson-Smart DJ. Intravenous dexamethasone for extubation of newborn infants (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 113. Ausejo M, Saenz A, Pham B, et al. The effectiveness of glucocorticoids in treating croup: meta-analysis. BMJ 1999; 319: Gotzsche PC, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998; 316: Van Everdingen AA, Jacobs JWG, Van Reesema DRS, et al. Low-dose prednisolone therapy for patients with early active rheumatoid arthritis: clinical efficacy, diseasemodifying properties, and side-effects. Ann Intern Med 2002: 136: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications. BNF for children London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications, 2005: Bellamy R. Pneumocystis pneumonia in people with HIV. BMJ Clinical Evidence [online] 2007 Feb [Cited 2007 May 25]. Available from: <http://clinicalevidence.bmj. com/ceweb/conditions/hiv/2501/2501.jsp> Dennis RJ, Solarte I, FitzGerald JM. Asthma. BMJ Clinical Evidence [online] 2007 Feb [Cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/ conditions/rdc/1501/1501.jsp> Nicholas R, Chataway J. Multiple sclerosis. BMJ Clinical Evidence [online] 2007 Feb [cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/ conditions/nud/1202/1202_i2.jsp> Walker-Bone K, Fallow S. Rheumatoid arthritis. BMJ Clinical Evidence [online] 2007 Feb [cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/ conditions/msd/1124/1124_i19.jsp> Choy EHS, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005; 44 (11): Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 123. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 124. Suarez-Almazor ME, Belseck E, Shea BJ, Tugwell P, Wells G. Methotrexate for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update

7 125. Suarez-Almazor ME, Belseck E, Shea BJ, Tugwell P, Wells G. Sulfasalazine for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 126. Suarez-Almazor ME, Belseck E, Shea BJ, Homik JJEH, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 127. Klasco RK, ed. USP DI Advice for Patients [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX; [Cited 2006 Oct 5]. Available form: <http://www.periodicos.capes.gov.br> Klasco RK, editor. USP DI. Advice for the Patients [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX; [Cited 2007 May 5]. Available from: <http://www.periodicos.capes.gov.br> Underwood M. Gout. In: BMJ Clinical Evidence, Web publication date: 01 Feb 2007 (base don June 2006 search) [Cited 2007 Jul 07] 130. Schlesinger N, Schumacher R, Catton M, Maxwell L. Colchicine for acute gout (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 131. Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007; 19(2): Lubianca Neto JF. Antialérgicos. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Pinheiro RM, Wannmacher. Farmacologia dos autacóides. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3 a ed. Rio de Janeiro: Guanabara Koogan; 2007: Simons FER. Advances in H1-antihistamines. New Engl J Med 2004; 351: British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 53 th. ed. London: BMJ Publishing Group and APS Publishing; Available from: <http://www.bnf.org> Escola Nacional de Saúde Pública. Núcleo de Assistência Farmacêutica. Fundamentos farmacológico-clínicos dos medicamentos de uso corrente. Rio de Janeiro: ENSP; Disponível em: <http://www.anvisa.gov.br/divulga/public/livro_eletronico/index. HTM> Stelmach R, do Patrocinio T Nunes M, Ribeiro M, Cukier A. Effect of treating allergic rhinitis with corticosteroids in patients with mild-to-moderate persistent asthma. Chest 2005; 128 (5): UpToDate online [Internet] version Epinephrine.In: UpToDate, Rose BD, editors, UpToDate, Waltham, MA, [Cited 2007 Dec 8]. Available from: <http:// e=misspell> Fuchs FD. Princípios gerais do uso de antimicrobianos. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3ª ed. Rio de Janeiro: Guanabara Koogan; 2004: Del Mar C. Sore throats and antibiotics. BMJ 2000; 320: Young JM, Ward JE. General practitioners use of evidence databases. Med J Aust 1999; 170: Wannmacher L. Uso indiscriminado de antibióticos e resistência microbiana: uma guerra perdida? In: OPAS. Uso racional de medicamentos Temas Selecionados, Brasília, 2004; 1(4): Avorn J, Solomon D H. Cultural and Economic Factors that (Mis) Shape Antibiotic Use: The Nonpharmacologic Basis of Therapeutics. Ann Intern Med 2000; 133: Wenzel R P, Edmond M B. Managing Antibiotic Resistance. N Engl J Med 2000; 343: Wannmacher L. Antibióticos betalactâmicos. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3 a ed. Rio de Janeiro: Guanabara Koogan; 2007:

8 146. Fuchs FD. Antibióticos betalactâmicos. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Matsumoto T, Muratani T. Newer carbapenems for urinary tract infections. Int J Antimicrob Agents 2004, 24 (suppl 1):S35 S WHO Expert Committee on the Selection and Use of Essential Medicines. The Selection and Use of Essential Medicines: report of the WHO Expert Committee, Geneva; [WHO Technical Report Series; 933:16.] 149. Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11(2): Reese RE, Betts RF. Antibiotic uses. In: Betts RF, Chapman SW, Penn RL, eds. Reese and Betts a pratical approach to infectious diseases. 5 th. ed. Philadelphia: Lippincott Williams & Wilkins, 2003: Reese RE, Betts RF. Principles of Antibiotic Use. In: Betts RF, Chapman SW, Penn RL, eds. Reese and Betts a practical approach to infectious diseases. 5 th. ed. Philadelphia: Lippincott Williams& Wilkins; 2003: Petri WA. Penicilins, cephalosporins, and other β-lactam antibiotics. In: Brunton LL, Lazo JS, Parker KLL, eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill; 2006: Giordano PA, Elston D, Akinlade BK, Weber K, Notario GF, Busman TA, Cifaldi M, Nilius AM. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults. Curr Med Res Opin 2006; 22 (12): Page CP, Bohnen JM, Fletcher JR, McManus AT, Solomkin JS, Wittmann DH. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg 1993; 128: Hoffman B, Page C, Curtis M, Walker M, Sutter M. Farmacologia integrada. 2 a ed. São Paulo: Manole; Erman M, Akova M, Akan H, Korten V, Ferhanoglu B, Koksal I, Cetinkaya Y, Uzun O, Unal S; Febrile Neutropenia Study Group of Turkey. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. Scand J Infect Dis 2001; 33 (11): Mustafa MM, Carlson L, Tkaczewski I, McCracken GH Jr, Buchanan GR. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001; 20 (3): Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, Maravi-Poma E, Torres-Marti A, Nava J, Martinez-Pellus A, Palomar M, Barcenilla F; Spanish Collaborative Group for the Study of Severe Infections. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001; 27 (3): Moellering RC, Swartz MN. Drug therapy: The newer cephalosporins. N Engl J Med 1976; 294(1): Machado ARL. Aminoglicosídeos. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a ed. Rio de Janeiro: Guanabara Koogan, 2004: Fonseca AL. Interações medicamentosas. 3 a. ed. Rio de Janeiro: Epub; p UpToDate 2007 [Database on the Internet]. Vincristine Sulfate. Available from: <http://www.uptodate.com> Wannmacher L. Sulfas, trimetoprima-sulfametoxazol e anti-sépticos urinários. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a ed. Rio de Janeiro: Guanabara Koogan; 2004: Erickson BA, Jang T, Schaeffer AJ. Chronic prostatitis. BMJ Clinical Evidence. Web publication date: 01 Feb 2007 (based on July 2006 search) [Cited 2007 Jul 08] 165. Reese RE, Betts RF, Gumustop B. Handbook of antibiotics. 3 rd. ed. Philadelphia: Lippincott Williams & Wilkins; 2000:

9 166. BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Guia de vigilância epidemiológica. Brasília, DF; Chambers HF. Protein synthesis inhibitors and miscellaneous antibacterial agents. In: Brunton LL, Lazo JS, Parker KLL, eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill; 2006: Fuchs FD. Macrolídeos. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a ed. Rio de Janeiro: Guanabara Koogan; 2004: Brocklehurst P, Rooney G. Interventions for treating genital chlamydia trachomatis infection in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 170. World Health Organization. The Selection and Use of Essential Medicines. Geneva: WHO Technical Report Series 920; 2004: Solomon AW et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004; 351(19): Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005; 353: Addy LD, Martin MV. Azithromycin and dentistry a useful agent? Br Dent J 2006; 197(13): Baciewicz AM, Al-Nimr A, Whelan P. Azithromycin-induced hepatoxicity. Am J Med 2005; 118 (12): Tarlow MJ. Macrolides in the management of streptococcal pharyngitis/tonsilitis. Pediatr Infect Dis J 1997; 16: Machado ARL. Fluorquinolonas. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a ed. Rio de Janeiro: Guanabara Koogan, 2004: Neuhauser MM, Weinstei RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units. Implications for fluoroquinolone use. JAMA 2003; 289: Fuchs FD. Glicopeptídeos, estreptograminas e oxazolidinonas. In: Fuchs, FD, Wannmacher L, Ferreira MB, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Susin C, Ferreira MBC. Anaerobicidas. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3 a ed. Rio de Janeiro: Guanabara Koogan; 2007: Behar P. Anaerobicidas: Metronidazol, Clindamicina e Lincomicina. In: Fuchs FD, Wannmacher L, Ferreira MBC (eds.). Farmacologia clínica: fundamentos da terapia racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Fuchs FD. Tetraciclinas e cloranfenicol. In: Fuchs, FD, Wannmacher L, Ferreira MB, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Reese RE, Betts RF. Antibiotic use. In: Betts RF, Chapman SW, Penn RL, eds. Reese and Betts A pratical approach to infectious diseases. 5 th. ed. Philadelphia: Lippincott Williams & Wilkins, 2003: Emerson PM, Burton M, Solomon AW, Bailey R, Mabey D. The SAFE strategy for trachoma control: Using operational research for policy, planning and implementation. Bull World Health Organ 2006; 84(8): Brasil. Ministério da Saúde. Tuberculose: guia de vigilância epidemiológica. Elaborado pelo Comitê Técnico Científico de Assessoramento à Tuberculose e Comitê Assessor para Co-infecção HIV-tuberculose. Brasília, DF: Ministério da Saúde: Fundação Nacional da Saúde, Souza LCA, editor. Dicionário de administração de medicamentos na enfermagem 2005/2006: AME. 4ª ed. Rio de Janeiro: Epub; Page CS. Farmacologia integrada. São Paulo: Manole, Hopewell PC. Tuberculosis control: how the world has changed since Bull WHO 2002; 80: 427.

10 188. Suarez PG, Watt CJ, Alarcon E, Portocarrero J, Zavala D, Canales R, et al. The dynamics of tuberculosis in response to 10 years of intensive effort in Peru. J Infect Dis 2001; 184: Khatri GR, Frieden TR. Rapid DOTS expansion in Índia. Bull WHO 2002; 80: Wannmacher L. Antituberculosos. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan, 2004: Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcântara F, et al. Communitybased therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: Ziganshina L, Garner P. Tuberculosis. BMJ Clinical Evidence. Web publication date: 01 Sep 2006 (based on July 2005 search) Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-hiv infected persons (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 194. Brasil. Ministério da Saúde. Fundação Nacional da Saúde. Tuberculose: guia de vigilância epidemiológica para Co-infecção HIV-tuberculose. Brasília, DF; Wannmacher L. Antituberculosos. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapia racional. 3 a ed. Rio de Janeiro: Guanabara Koogan; 2004: BRASIL. Ministério da Saúde. II Consenso brasileiro de tuberculose. Diretrizes brasileiras para tuberculose J Bras Pneumol 2004: 30(supl.1): Brasil. Ministério da Saúde. Fundação Nacional da Saúde. Guia de vigilância epidemiológica. 5 a ed. Brasília, DF: FUNASA, Wannmacher L. Profilaxia antiinfecciosa com antimicrobianos. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapia racional. 3 a ed. Rio de Janeiro: Guanabara Koogan; 2004: BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV Brasília, DF; Versão preliminar Bernardi C, Machado ARL. Hanseníase. In: Duncan DB, Schmidt MI, Giugliani ERJ, eds. Medicina ambulatorial: condutas de atenção primária baseadas em evidências. 3 a. ed. Porto Alegre: Artmed; 2004: Committee on Infectious Diseases. The Use of Systemic Fluoroquinolones. Am Acad Pediatr 2006; 118 (3): World Health Organization. WHO Model List of Essential Medicines for Children (October 2007). [Citado 2007 dez.15]. Available from: <http://www.who.int/ medicines/publications/essentialmedicines/en/index.html> Muzyka BC. Oral fungal infections. Dent Clin North Am 2005; 49(1): Milillo L, Lo Muzio L, Carlino P, Serpico R, Coccia E, Scully C. Candida-related denture stomatitis: a pilot study of the efficacy of an amorolfine antifungal varnish. Int J Prosthodont 2005; 18 (1): Wannmacher L. Antifúngicos. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2007: Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral candidiasis for patients with cancer receiving treatment (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 207. Pankhurst CL. Candidiasis (oropharyngeal). BMJ Clinical Evidence. Web publication date: 01 Nov 2005 (based on June 2006 search) Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92 (2): Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. A randomized, double-blind study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46:

11 210. Van Roey J, Haxaire M, Kamya M, Lwanga I, Katabira E. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 2004; 35(2): Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 212. Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 213. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 214. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 215. Machado ARL. Antifúngicos. In: Fuchs, FD, Wannmacher L, Ferreira MB, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Tavares W, Marinho LAC. Rotinas de diagnóstico e tratamento das doenças infecciosas e parasitárias. São Paulo: Atheneu; Machado ARL. Antifúngicos. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Shikanai-Yasuda1 MA, Telles Filho FQ, Mendes RP, Colombo AL, Moretti ML, et al. Consenso de Paracoccidioidomicose. Rev Soc Bras Med Trop 2006; 39(3): Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Lexi-Comp s Drug Information Handbook International. 13 rd. ed. Hudson, Ohio: Lexi-Comp; 2005: Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 221. Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 222. Crawford F, Hart R, Bell-Syer S, Torgerson D, Young P, Russell I. Topical treatments for fungal infections of the skin and nails of the foot (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 223. Suh JS, Sepkowitz KA. Opportunistic infections in HIV disease. In: Betts RF, Chapman SW, Penn RL, eds. Reese and Betts a pratical approach to infectious Diseases. 5 th. ed. Philadelphia: Lippincott Williams & Wilkins, 2003: Susin C, Ferreira MBC. Antivirais. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3ª ed. Rio de Janeiro: Guanabara Koogan; 2007: Gnann Jr JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347: Tyring SK, Douglas JM Jr, Corey L, Spruance SL, Esmann J. A randomized, placebocontrolled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Arch Dermatol 1998; 134: Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ. International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002;13: Wilhelmus KR. Therapeutic interventions for herpes simplex virus epithelial keratitis (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 229. Allen D, Dunn L. Aciclovir or valaciclovir for Bell s palsy (idiopathic facial paralysis) (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update

12 230. Klassen TP, Hartling L, Wiebe N, Belseck EM. Acyclovir for treating varicella in otherwise healthy children and adolescents (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 231. Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GFM, Vimalachandra D, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 232. Strippoli GF, Hodson EM, Jones CJ, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 233. Kuchenbecker RS. Antivirais. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 10, Available at: <http://aidsinfo.nih.gov> World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access. Recommendations for a public health approach rev. Geneva: WHO; Available from: <http://www.who.int/hiv/ pub/guidelines/adult/en/index.html> WHO Expert Committee on the Selection and Use of Essential Medicines. The Selection and Use of Essential Medicines: report of the WHO Expert Committee, [WHO Technical Report Series; 933] 237. Martin AM, Almeida CA, Cameron P, Purcell AW, Nolan D, James I, et al. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 2007; 21 (10): Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford GW. Antiretroviral postexposure prophylaxis (PEP) for occupational HIV exposure (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 239. Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 343: Brocklehurst P. Interventions for reducing the risk of mother-to-child transmission of HIV infection (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 241. Volmink J, Siegfried NL, Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 242. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de Doenças Sexualmente Transmissíveis e Aids. Recomendações para Profilaxia da Transmissão Vertical do HIV e Terapia Anti-Retroviral em Gestantes. Brasília, DF; Legorreta A, Yu A, Chernicoff H, Gilmore A, Jordan J, Rosenzweig JC. Adherence to combined Lamivudine + Zidovudine versus individual components: a communitybased retrospective medicaid claims analysis. AIDS Care 2005; 17 (8): Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS. Efficacy, safety, and adherence with a twice-daily combination lamivudine/ zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 2000; 14 (6): Brasil. Ministério da Saúde Secretaria de Vigilância à Saúde, Programa Nacional de DST e Aids. Guia de tratamento clínico da infecção pelo HIV em crianças. Brasília, DF; Journot V, Chene G, De Castro N, Rancinan C, Cassuto JP, Allard C, et al; ALIZE Study Group. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis 2006; 43 (2): 270.

13 247. Gupta SB, Pujari SN, Joshi SR, Patel AK; AIDS Society of India Guidelines Development Committee. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India. J Assoc Physicians India 2006; 54: Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, et al; Imea 011/ANRS Study Group. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS 2003; 17 (7): Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda. HIVNET. 012 randomised trial. Lancet 1999; 354: Siegfried NL, Deventer PJU, Mahomed FA, Rutherford GW. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update 251. Shahara AI, Rocky DC. Gastroesophageal Variceal Hemorrhage. N Engl J Med 2001; 345 (9): BRASIL. Ministério da Saúde. Guia de tratamento clínico da infecção pelo HIV em crianças. Brasília, DF: Ministério da Saúde, Coordenação Nacional de DST e Aids; Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF; for the Tenofovir DF Expanded Access Team. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21(10): Johnson MA, Gathe JC Jr, Podzamczer D, Molina JM, Naylor CT, Chiu YL, et al.. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43 (2): Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20 (5): World Health Organization. Reviewer N o 1 check list for application for addition: tenofovir disopropil fumarate (TDF). [Cited 2007 Jul 12]. Available from: <http:// mednet3.who.int/eml/expcom/expcom15/applications.htm#f> WHO Expert Committee on the Selection and Use of Essential Medicines. Report of the Who Expert Committee on the Selection and Use of Essential Medicines. Geneva: WHO; Available from: <http://www.who.int/medicines/services/ expertcommittees/essentialmedicines/15_may_trsreport.pdf> Kuchenbecker RS. Antivirais. In: Fuchs, FD, Wannmacher L, Ferreira MBC, Eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. Ed. Rio de Janeiro: Guanabara Koogan; 2004: Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al, for the M Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, et al, MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 2003; 188: Zorrilla CD, Van Dyke R, Bardeguez A, Acosta EP, Smith B, Hughes MD, et al. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrob Agents Chemother 2007; 51(6): Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human

14 immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2007; 51 (6): Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. New Microbiol 2007; 30 (2): Simpson KN, Jones WJ, Rajagopalan R, Dietz B. Cost Effectiveness of Lopinavir/ Ritonavir Compared with Atazanavir plus Ritonavir in Antiretroviral-Experienced Patients in the US. Clin Drug Invest 2007; 27(7): Boyer E, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352: Addiss D, Gamble C, Garner P, Gelband H, Ejere H. Albendazole for lymphatic filariasis (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 267. Loukas A, Hotez PJ. Chemotherapy of helmintic infections. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill; 2006: Sunish IP, Rajendran R, Mani TR, Munirathinam A, Reuben R, Dash AP. Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years. Parasitol Int 2006; 55 (3): Rajendran R, Sunish IP, Mani TR, Munirathinam A, Arunachalam N, Satyanarayana K, Dash AP. Community-based study to assess the efficacy of DEC plus ALB against DEC alone on bancroftian filarial infection in endemic areas in Tamil Nadu, south India. Trop Med Int Health 2006; 11 (6): Yongyuth P, Koyadun S, Jaturabundit N, Jariyahuttakij W, Bhumiratana A. Adverse reactions of 300 MG diethylcarbamazine, and in a combination of 400 MG albendazole, for a mass annual single dose treatment, in migrant workers in Phang Nga province. J Med Assoc Thai 2007; 90 (3): Stolk WA, VAN Oortmarssen GJ, Pani SP, DE Vlas SJ, Subramanian S, DAS PK, Habbema JD. Effects of ivermectin and diethylcarbamazine on microfilariae and overall microfilaria production in bancroftian filariasis. Am J Trop Med Hyg 2005; 73 (5): Urbani C, Albonico M. Anthelminthic drug safety and drug administration in the control of soil-transmitted helminthiasis in community campaigns. Acta Trop 2003; 86: Montresor A, Awasthi S, Crompton DW. Use of benzimidazoles in childrenyounger than 24 months for the treatment of soil-transmitted helminthiasis. Acta Trop 2003; 86: Dans L, Martínez E. Amoebic dysentery. In: BMJ Clinical Evidence [Web publication date: 01 Jan 2007 (based on July 2006 search) 275. Escobedo AA, Canete R, Gonzalez ME, Pareja A, Cimerman S, Almirall P. A randomized trial comparing mebendazole and secnidazole for the treatment of giardiasis. Ann Trop Med Parasitol 2003; 97: Cimerman B, Camilo Coura L, C Salle JM, Gurvitz R, Rocha RS, Bandeira S, et al. Evaluation of secnidazole gel and tinidazole suspension in the treatment of giardiasis in children. Braz J Infect Dis 1997; 1: Freitas LF, Chaves GC, Wannmacher L, Osorio-de-Castro CGS. Malária não complicada por Plasmodium vivax e P. falciparum no Brasil: evidências sobre fármacos isolados e associações medicamentosas empregados em esquemas terapêuticos recomendados pelo protocolo terapêutico oficial. [Uncomplicated Plasmodium vivax and P. falciparum malaria in Brazil: evidence on isolated and associated drug treatments recommended by official therapeutic guidelines.] Cad. Saúde Pública, Rio de Janeiro 2007; 23: Poole S. The use of antimalarial drugs: report of an informal consultation. Geneva: Roll Banck Malaria/World Health Organization; p McIntosh HM, Jones KL. Chloroquine or amodiaquine combined with sulfadoxinepyrimethamine for treating uncomplicated malaria (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update

15 280. Garner P, Gülmezoglu AM. Drugs for preventing malaria in pregnant women (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 281. Meremikwu MM, Omari AAA, Garner P. Chemoprophylaxis and intermittent treatment for preventing malaria in children (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 282. Graves P, Gelband H. Vaccines for preventing malaria (pre-erythrocytic) (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 283. Graves P, Gelband H. Vaccines for preventing malaria (blood-stage) (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 284. Omari A, Garner P. Malaria: severe, life-threatening (updated). [Web publication date: 01 Jul 2007 (based on December 2006 search)] 285. Afolabi BB, Okoromah CN. Intramuscular artemether for treating severe malaria (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 286. Bukirwa H, Orton L. Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 287. Taylor-Robinson D, Jones K, Garner P. Malaria: uncomplicated, caused by Plasmodium falciparum. In: BMJ Clinical Evidence. [Web publication date: 01 Oct 2006 (based on September 2006 search)] Croft AMJ, Garner P. Mefloquine for preventing malaria in non-immune adult travellers (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 289. Galappaththy GNL, Omari AAA, Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 290. Eisenhut M, Omari AAA. Intrarectal quinine for treating Plasmodium falciparum malaria (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 291. Shapiro TA, Goldberg DE. Chemotherapy of protozoal infections. Malaria. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill; 2006: Petersen E. Toxoplasmosis. Semin Fetal Neonatal Med 2007; 12 (3): Peyron F, Wallon M, Liou C, Garner P. Treatments for toxoplasmosis in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 294. Peyron F, Wallon M. Options for the pharmacotherapy of toxoplasmosis during pregnancy. Expert Opin Pharmacother 2001; 2 (8): Gilbert RE, Harden M, Stanford MR. Antibiotics versus control for toxoplasma retinochoroiditis (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 296. Olliaro P. Congenital toxoplasmose. [Web publication date: 01 Jun 2004 (based on March 2004 search) Phillips MA, Stanley SL. Chemotherapy of protozoal infections. In: Brunton LL, Lazo JS, Parker KL eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill, 2006: Villar JC, Villar LA, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 299. Miranda ES, Carvalho RR, Miekeley N, Paumgartten F Jr. Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat. Reprod Toxicol 2005; 21(3): Konkewicz LR. Controle de infecção em Odontologia. Anti-sépticos e desinfetantes. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para Dentistas. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2007: Zambon JJ. Controle da infecção. In: Genko RJ, Cohen DW, Goldman HM. Periodontia contemporânea. São Paulo: Santos; 1996:

16 302. Miguel JMM. Controle de infecção no consultório ortodôntico. Rev SBO 1997; 3: Nesi MAM. Prevenção de contágios nos atendimentos odontológicos. Novos paradigmas e protocolos de procedimentos. São Paulo: Atheneu; p Associação Paulista de Estudos em Controle de Infecção Hospitalar (APECIH). Controle de Infecção na prática odontológica. São Paulo: APECIH; p Oppermann CM, Pires LC. Manual de Biossegurança para Serviços de Saúde. Porto Alegre: Secretaria Municipal de Saúde p Konkewicz L. Controle de Infecção em Odontologia. In: Souza VHS, Mozachi N. O Hospital. Manual do Ambiente Hospitalar. Curitiba: Maxi Gráfica; 2005: Occupational Safety and Health Administration (OSHA). Best practices for the safe use of glutaraldehyde in health care. US Department of Labor; p Rideout K, Teschke K, Dimich-Ward H, Kennedy SM. Considering risks to healthcare workers from glutaraldehyde alternatives in high-level disinfection. J Hosp Infect 2005; 59: Cardoso CL, Pereira HH, Zequim JC, Guilhermetti M. Effectiveness of hand-cleasing agents for removing Acinetobacter baumannii strain from contaminated hands. Am J Infect Control 1999; 27: Lucet JC, Rigaud MP, Mentre F, Kassis N, Deblangy C, Andremont A, et al. Hand contamination before and after different hand hygiene techniques: a randomized clinical trial. J Hosp Infect 2002; 50: Nishimura C. Comparison of the antimicrobial efficacy of povidone-iodine, povidone-iodine-ethanol, and chlorhexidine gluconate-ethanol surgical scrubs. Dermatology 2006; 212 (suppl 1): Chabner BA, Amrein PC, Druker BJ, Michaelson MD, Mitsiades CS, Goss PE, et al. Antineoplastic agents. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman s the pharmacological basis of therapeutics. 11 th. ed. New York: McGraw-Hill: 2006: McCarthy M. Number of cancer drugs in development rises in the USA. Lancet Oncol 2001; 2 (5): Cabanillas F et al. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol 1998; 9: Moskowitz C. Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemother Pharmacol 2002; 49: S9-S McBride NC et al. Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation. Leuk Lymphoma 1999; 35: Thomas DA et al. Hyper-CVAD program in Burkitt s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17(8): Siu LL, Moore MJ. Use of mesna to prevent ifosfamide-induced urotoxicity. Support Care Cancer 1998; 6(2): Cancer Care Ontario Practice Guidelines Initiative. Fludarabine in intermediate- and high-risk chronic lymphocytic leukemia. (Practice guideline n o 6-1). Summary July Available from: <http://hiru.mcmaster.ca/ccopgi/guidelines.htlm> Dearden CE, Matutes E, Hildtich BL, Swansbury GJ, Catovsky D. Long-term followup of patients with hairy cell leukemia after treatment with pentostatin and cladribine. Br J Haematol 1999; 106: Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Drug information handbook international. 13 rd. ed. Hudson, Ohio: Lexi-Comp; 2005: Bittencourt H, Brunstein C. Antineoplásicos.In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan, Physicians Information and Education Resource PIER. American College of Physicians. Disponível em: <http://pier.acponline.org/physicians/diseases/ html> Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for treatment of advanced Hodgkin s disease. J Clin Oncol 2003; 21:

17 325. Cancer Care Ontario Practice Guidelines Initiative. Epirubicin, as a single agent or in combination, for metastatic breast cancer. (Practice guideline n o 1-6). Summary April Available from: <http://hiru.mcmaster.ca/ccopgi/guidelines.htlm> Zaniboni A, Bolognesi A, Arnoldi E, Tabiadon D, Barni S, Intini C. Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients. AntiCancer Drugs 1998; 9: Anderlini P, Giralt S, Andersson B, et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin s disease. Bone Marrow Transpl 2000: 26; Zinzani PL et al. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-hodgkin s lymphoma. Leuk Lymphoma 1995; 19: Navo M, Kunthur A, Badell ML, Coffer LW 2nd, Markman M, Brown J, Smith JA. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006; 103 (2): Kandel MJ, Loehr A, Harter P, et al. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15 (5): Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80 (10): Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100 (8): Danson S, Middleton MR, O Byrne KJ, Clemons M, Ranson M, Hassan J, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2003; 98 (3): Cancer Care Ontario Practice Guidelines Initiative. Chemotherapy for recurrent ovarian cancer previously treated with platinum. (Evidence Summary Report n o 4-3). Summary September Available from: <http://hiru.mcmaster.ca/ccopgi/ guidelines.htlm> Stebbing J, Slater S, Slevin M. Breast cancer (metastatic). BMJ Clinical Evidence.[Cited 2007 May 25]. Available from: <http://www.clinicalevidence.com/ceweb/conditions/ woh/0811/0811.jsp> Ackland SP. Drug treatment of breast cancer. Aust Prescr 1998; 21 (1):15-9. [Cited 2007 May 25]. Available from: <http://www.australianprescriber.com/ magazine/21/1/15/9/> Fischer B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxyfen for lymph node-negative breast cancer. Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Ccncer Inst 2001; 93: Klijn JG, Beex LV,Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal meatastatic breast cancer: a randomized trial. J Natl Ccncer Inst 2000; 92: Strasser-Weippl K, Goss PE. Counteracting estrogen as breast cancer prevention. In: Kellof GJ, Hawk ET, Sigman CC, eds. Cancer Chemoprevention. Totwa, NJ: Human Press; 2005: O Reagan RM, Jordan VC. Tamoxifen to raloxifene and beyond. Semin Oncol 2001; 28: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast cancer risk reduction. V Available from: <http://www.nccn.org/ prefessionals/physician _ gls/pdf/breast_risk.pdf> McLachlan S-A. Managing health women at risk of breast câncer. Aust Prescr 2002; 25: Baum M, Budzar AU, Cuzick J, et al. Anatrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women

18 with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: Wellington K, Faulds DM. Anatrozole in early breast cancer. Drugs 2002; 62: Nabholtz JM, Reese D Anatrozole in the management of breast cancer. Expert Opin Pharmacother 2002; 3: Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy. Am J Med 2002; 112: Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a metaanalysis of randomized controlled trials. J Clin Oncol 2004; 22: Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: Dale DC. Filgrastim anniversary supplement: reviewing 10 years of clinical experience, a seminar-in-print. Drugs 2002; 62 (suppl 1): Cottle TE, Fier CJ, Donadieu J, Kinsey SE. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin Hematol 2002; 39: Ozer H et al update of recommendations for the use of hematopoietic colonystimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18: Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005; 23: Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colonystimulating factor. Clin Infect Dis 2000; 30: Carr R, Modi N, Doré C. G-CSF and GM-CSF for treating or preventing neonatal infections (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 355. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 356. Brandão AMB. Antieméticos. In: Fuchs FD, Wannmacher L, Ferreira MBC (eds.). Farmacologia clínica: fundamentos da terapêutica racional. 3 a. ed. Rio de Janeiro: Guanabara Koogan; 2004: Roila F, Ballatori E, Tonato M, Del Favero A. 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer 1997; 33 (9): Del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting. Results of a meta-analysis of randomized controlled trials. Cancer 2000; 89: Tramèr MR, Reynolds DJ, Stoner NS, Moore RA, McQuay HJ. Efficacy of 5-HT 3 receptor antagonist in radiotherapy-induced nausea and vomiting: a quantitative systematic review. Eur J Cancer 1998; 34: Kawashima H, Tanaka T, Kuratsukuri K, Uchida J, Sugimura K, Tamada S, Nishisaka N, Kumata K, Iwai Y, Ikemoto S, Ezaki K, Nakatani T. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-i collagen level in patients with increasing prostate-specific antigen levels. Urol Int 2007; 78(4): Fuleihan Gel-H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, Shamseddine A. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90 (6):

19 362. Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, et al.; Gruppo Italiano Studio Linfomi. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007; 48 (1): Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 364. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintenance of remission in Crohn s disease (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 365. Timmer A, McDonald JWD, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 366. Wells G, Haguenauer D, Shea B, Suarez-Almazor ME, Welch VA, Tugwell P. Cyclosporine for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 367. Durkan A, Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 368. Evans DJ, Cullinan P, Geddes DM, Walters EH, Milan SJ, Jones PW. Cyclosporin as an oral corticosteroid sparing agent in stable asthma (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 369. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 370. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 371. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 372. BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications. BNF for children London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, RCPCH Publications, 2005: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain. British National Formulary. 50 th. ed. London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain; September 2005: Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 375. Edelson PJ. Immunizations. In: Betts RF, Chapman SW, Penn RL, eds. Reese and Betts s a practical approach to infectious diseases. 5 th ed. Philadelphia: Lippincott Williams & Wilkins; 2003: Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 377. Schroth RJ, Hitchon CA, Uhanova J, Noreddin A, Taback SP, Moffatt MEK, Zacharias JM. Hepatitis B vaccination for patients with chronic renal failure (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 378. Jefferson TO, Rivetti D, Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 379. Cates CJ, Jefferson TO, Bara AI, Rowe BH. Vaccines for preventing influenza in people with asthma (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update

20 380. Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 381. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 382. Demicheli V, Barale A, Rivetti A. Vaccines for women to prevent neonatal tetanus (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 383. Universidade Federal do Rio de Janeiro. Centro de Vacinação de Adultos (CVA). [Citado 2007 jul. 26]. Disponível em: <http://www.cva.ufrj.br/vacinas/ft-v.html> Secretaria de Estado da Saúde. São Paulo. Centro de Vacinação Estadual. Norma do Programa de imunização. 2 a. ed. São Paulo: Secretaria de Estado da Saúde; Brasil. Ministério da Saúde. Manuais técnicos/ms. Disponível em: <http://www.vacinas. org.br/novo/manuais_t_cnicos/manual_de_eventos_adversos/evenadv06.htm> São Paulo (Estado). Secretaria de Estado da Saúde. Instituto Butantan. Informações referentes aos medicamentos do Instituto Butantan (Soros e Vacinas) que irão constar no Formulário Terapêutico Nacional FTN. São Paulo: Instituto Butantan; Salisbury D, Ramsay M, Noakes K eds. Immunisation against infectious disease. London: The Stationery Office; [Cited 2007 Jul 10]. Available from: <http:// DH_ > Brasil. Portaria Nº de 17 de julho de Institui em todo o território nacional, os calendários de Vacinação da Criança, do Adolescente, do Adulto e do Idoso. Brasília, DF; [Citado 2007 maio 27]. Disponível em: <http://www.in.gov.br/ materias/xml/do/secao1/ xml> Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Programa Nacional de Imunizações. Manual de vigilância epidemiológica de eventos adversos pós-vacinação. Brasília, DF: Ministério da Saúde; Fundação Instituto Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos. Vacina contra meningite meningocócica A e C. Bula do produto. [Citado 2008 jan. 11]. Disponível em: <http://www.bio.fiocruz.br/interna/pdf/ bmdco_090_01bmeningite.pdf> Instituto Finlay. Habana, Cuba. Centro de Investigación-Produción de Vacunas. Vacuna antemeningocócica BC (VA-MENGOC-BC ). La Habana, Cuba. [Citado 2007 ago. 20]. Disponível em: <http://www.finlay.sld.cu/cartera/vamengocbc.htm> National Health & Medical Research Council. Canberra, Australian, (NHMRC). The Australian Immunisation Handbook. 8 th. ed. Canberra: NHMRC; Brasil. Ministério da Saúde. Coordenação de Imunizações e Auto-Suficiência em Imunobiológicos. Manual dos Centros de Referência para Imunobiológicos Especiais. Brasília, DF: Ministério da Saúde; São Paulo (Estado). Secretaria de Estado da Saúde. Coordenação dos Institutos de Pesquisa. Centro de Vigilância Epidemiológica. Informe Técnico: Vacina combinada contra DTP e Hib. São Paulo, SP; [Citado 2007 dez. 08]. Disponível em: <ftp:// ftp.cve.saude.sp.gov.br/doc_tec/imuni/tetra_valente.pdf> Lopez FA, Sanders CV. Skin and soft tissue infections. In: Betts RF, Chapman SW, Penn RL, eds. Reese and Betts s a practical approach to infectious diseases. 5 th. ed. Philadelphia: Lippincott Williams & Wilkins; 2003: Hodson EM, Jones CA, Strippoli GFM, Webster AC, Craig JC. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients (Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update 397. Parant O. Comparison of the efficacy of different methods for the prevention of anti-d allo-immunization during pregnancy: targeted strategy limited to risk situations or associated with systematic prevention in the 3rd trimester. J Gynecol Obstet Biol Reprod (Paris) 2006; 35(1 Suppl):1S93-1S103.

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957

More information

Chapter 10 Human Immuno Deficiency Virus Infection

Chapter 10 Human Immuno Deficiency Virus Infection 143 Chapter 10 Human Immuno Deficiency Virus Infection Chapter 10 Human Immuno Deficiency Virus Infection...143 HIV infection...144 Clinical Features...146 Clinical Staging of HIV infection recommended

More information

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo * This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Journal Presentation

More information

Basic Reference Format

Basic Reference Format Basic Reference Format The following Referencing Format is adapted from the AMA Manual of Style, 9 th edition. 1 If you have questions about referencing an item, please refer to the AMA Manual of Style,

More information

Two Days of Dexamethasone Versus 5 Days of Prednisone in the Treatment of Acute Asthma: A Randomized Controlled Trial

Two Days of Dexamethasone Versus 5 Days of Prednisone in the Treatment of Acute Asthma: A Randomized Controlled Trial GENERAL MEDICINE/ORIGINAL RESEARCH Two Days of Dexamethasone Versus 5 Days of Prednisone in the Treatment of Acute Asthma: A Randomized Controlled Trial Joel Kravitz, MD, FRCPSC, Paul Dominici, MD, Jacob

More information

TREATMENT OF STI CONTACTS

TREATMENT OF STI CONTACTS This decision support tool is effective as of October 2014. For more information or to provide feedback on this or any other decision support tool, email certifiedpractice@crnbc.ca TREATMENT OF STI CONTACTS

More information

USI Master Policy Information

USI Master Policy Information Policy I.D. Gender A.B. (#327) M 86 United of Omaha $ 1,000,000.00 A.B. (#430) - (#436) M 86 Metlife $ 2,000,000.00 A.G. #1 (#371), (#610), (#624) M Conseco Life $ 3,125,000.00 10/Apr/10 A.G. #2 (#380),

More information

Basic Reference Format

Basic Reference Format Basic Reference Format The following Referencing Format is adapted from the AMA Manual of Style, 9 th edition. 1 If you have questions about referencing an item, please refer to the AMA Manual of Style,

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Dosing information in renal impairment

Dosing information in renal impairment No. Drug name Usual dose Adjustment for Renal failure estimated CrCl (ml/min) Aminoglycoside antibiotics 1 Amikacin 2 Gentamicin 7.5 mg /kg q 12 hr > 50-90 7.5 mg/kg q 12 hr 10-50 7.5 mg/kg q 24 hr < 10

More information

Before, Frank's immune cells could

Before, Frank's immune cells could Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

PROVEN NON-INVASIVE TREATMENT FOR RHEUMATOID ARTHRITIS

PROVEN NON-INVASIVE TREATMENT FOR RHEUMATOID ARTHRITIS PROVEN NON-INVASIVE TREATMENT FOR RHEUMATOID ARTHRITIS BIONICARE HAND SYSTEM Non-drug, non-invasive Adjunctive therapy For patients symptomatic despite current therapy For patients intolerant to drug

More information

Lyme Disease in Pregnancy. Dr Sarah Chissell Consultant Obstetrician William Harvey Hospital, Kent

Lyme Disease in Pregnancy. Dr Sarah Chissell Consultant Obstetrician William Harvey Hospital, Kent Lyme Disease in Pregnancy Dr Sarah Chissell Consultant Obstetrician William Harvey Hospital, Kent Conflict of interest My son has chronic Lyme disease Infections in pregnancy Transplacental infection Perinatal

More information

Disease Site Breast. Less than 120 kg: Cefazolin 2 grams IV Greater than or equal to 120 kg: Cefazolin 3 grams IV. Head & Neck

Disease Site Breast. Less than 120 kg: Cefazolin 2 grams IV Greater than or equal to 120 kg: Cefazolin 3 grams IV. Head & Neck Patients scheduled for surgery should have the following antibiotics administered prior to their procedure Vancomycin and Ciprofloxacin are to be initiated 60 to 120 minutes prior to incision and all other

More information

Lymphoma: The Roleof Nurses in the Treatment Process

Lymphoma: The Roleof Nurses in the Treatment Process Lymphoma: The Roleof Nurses in the Treatment Process Sarah Liptrott MSc,BN(Hons), RN Istituto Europeo di Oncologia, Milan (IT) EBMT Swiss Study Day 2014, Zurich, Switzerland LymphomaManagement Watch &

More information

Single Blind, Comparative Study of Ketoprofen Cream Vs Diclofenac and Piroxicam Cream in Management of Rheumatoid Arthritis Patients

Single Blind, Comparative Study of Ketoprofen Cream Vs Diclofenac and Piroxicam Cream in Management of Rheumatoid Arthritis Patients International Journal of Pharma Sciences Vol. 4, No. 5 (2014): 697-701 Research Article Open Access ISSN: 2320-6810 Single Blind, Comparative Study of Ketoprofen Vs Diclofenac and Piroxicam in Management

More information

THE COMPARATIVE OUTCOME OF TOPICAL FORMULATIONS IN RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY IN 125 PATIENTS OF AGE GROUPS 40-60 YEARS:

THE COMPARATIVE OUTCOME OF TOPICAL FORMULATIONS IN RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY IN 125 PATIENTS OF AGE GROUPS 40-60 YEARS: Page972 Indo American Journal of Pharmaceutical Research, 2015 ISSN NO: 2231-6876 THE COMPARATIVE OUTCOME OF TOPICAL FORMULATIONS IN RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY IN 125 PATIENTS OF AGE GROUPS

More information

A. Ketorolac*** B. Naproxen C. Ibuprofen D. Celecoxib

A. Ketorolac*** B. Naproxen C. Ibuprofen D. Celecoxib 1. A man, 66 years of age, with a history of knee osteoarthritis (OA) is experiencing increasing pain at rest and with physical activity. He also has a history of depression and coronary artery disease.

More information

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use

More information

C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY

C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY I. TREATMENT PLANNING GUIDELINES As part of informed consent, the clinician should carefully explain the risks and benefits of oral and maxillofacial surgery

More information

A BIBLIOGRAPHY OF PEER-REVIEWED JOURNAL ARTICLES

A BIBLIOGRAPHY OF PEER-REVIEWED JOURNAL ARTICLES ANESTHESIA CLOSED CLAIMS PROJECT A BIBLIOGRAPHY OF PEER-REVIEWED JOURNAL ARTICLES PROJECT OFFICE Anesthesia Closed Claims Project Department of Anesthesiology and Pain Medicine University of Washington

More information

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR DENTAL MEDICINE

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR DENTAL MEDICINE DECEMBER 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Gingivitis

More information

International Journal of Pharma and Bio Sciences EFFICACY OF CHLOROQUINE IN MANAGEMENT OF CHIKUNGUNYA: A PHASE IV CLINICAL TRIAL

International Journal of Pharma and Bio Sciences EFFICACY OF CHLOROQUINE IN MANAGEMENT OF CHIKUNGUNYA: A PHASE IV CLINICAL TRIAL International Journal of Pharma and Bio Sciences RESEARCH ARTICLE PHARMACOLOGY EFFICACY OF CHLOROQUINE IN MANAGEMENT OF CHIKUNGUNYA: A PHASE IV CLINICAL TRIAL Corresponding Author DR. DILIP KUMAR RENAPURKAR

More information

CODES FOR PHARMACY ONLINE CLAIMS PROCESSING

CODES FOR PHARMACY ONLINE CLAIMS PROCESSING S FOR PHARMACY ONLINE CLAIMS PROCESSING The following is a list of error and warning codes that may appear when processing claims on the online system. The error codes are bolded. CODE AA AB AI AR CB CD

More information

Summary of the risk management plan (RMP) for Accofil (filgrastim)

Summary of the risk management plan (RMP) for Accofil (filgrastim) EMA/475472/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim) This is a summary of the risk management plan (RMP) for Accofil, which details the measures to be taken in order to ensure

More information

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)

More information

Varicella and Varicella Vaccine

Varicella and Varicella Vaccine Varicella and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp

More information

Coordinator of the Brazilian Institute of Health Technology Assessment Coordinator, Hypertension Unit, Division of Cardiology

Coordinator of the Brazilian Institute of Health Technology Assessment Coordinator, Hypertension Unit, Division of Cardiology FLÁVIO DANNI FUCHS Current Administrative and Academic Appointments Administrative Academic Coordinator of the Brazilian Institute of Health Technology Assessment Coordinator, Hypertension Unit, Division

More information

Hematologic Malignancies/Stem Cell Transplantation Program Clinical Section UCLA Health System Los Angeles, CA 90095

Hematologic Malignancies/Stem Cell Transplantation Program Clinical Section UCLA Health System Los Angeles, CA 90095 Clinical Section UCLA Health System Los Angeles, CA 90095 CS 6.2 DIAGNOSIS AND MANAGEMENT OF INTERSTITIAL PNEUMONIA Location: Clinical Section Supersedes/Replaces: B3.421g Document drive\path\name Effective

More information

A systematic review of the uses and contraindications of epinephrine in local anesthesia in the dermatologic setting

A systematic review of the uses and contraindications of epinephrine in local anesthesia in the dermatologic setting A systematic review of the uses and contraindications of epinephrine in local anesthesia in the dermatologic setting Syril Keena Que, MD; James Whalen, MD University of Connecticut Health Center Department

More information

Oropharyngeal Candidiasis in Patients with AIDS

Oropharyngeal Candidiasis in Patients with AIDS Oropharyngeal Candidiasis in Patients with AIDS Information included in this particular presentation is for educational purposes only. Oral Thrush is not one of the indications for which Diflucan is donated

More information

Antiretroviral therapy for HIV infection in infants and children: Towards universal access

Antiretroviral therapy for HIV infection in infants and children: Towards universal access Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous

More information

10. Treatment of peritoneal dialysis associated fungal peritonitis

10. Treatment of peritoneal dialysis associated fungal peritonitis 10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of

More information

1.- L a m e j o r o p c ió n e s c l o na r e l d i s co ( s e e x p li c a r á d es p u é s ).

1.- L a m e j o r o p c ió n e s c l o na r e l d i s co ( s e e x p li c a r á d es p u é s ). PROCEDIMIENTO DE RECUPERACION Y COPIAS DE SEGURIDAD DEL CORTAFUEGOS LINUX P ar a p od e r re c u p e ra r nu e s t r o c o rt a f u e go s an t e un d es a s t r e ( r ot u r a d e l di s c o o d e l a

More information

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to

More information

Influenza Vaccine Frequently Asked Questions. Influenza Control Program

Influenza Vaccine Frequently Asked Questions. Influenza Control Program Influenza Vaccine Frequently Asked Questions Influenza Control Program Influenza or the flu can be a serious contagious disease, which is spread by droplet transmission through close contact with an infected

More information

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare

More information

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine

More information

Comparison of pharmacokinetics and efficacy of oral and injectable medicine

Comparison of pharmacokinetics and efficacy of oral and injectable medicine Comparison of pharmacokinetics and efficacy of oral and injectable medicine Outline Background Results Antibiotics Non steroidal anti-inflammatory drugs (NSAIDs) Vitamins Conclusions and recommendations

More information

Chapter 8. Vaccine Administration

Chapter 8. Vaccine Administration Chapter 8 Vaccine Administration 8.1 Objectives To understand how to prepare vaccines for immunisation To understand how to administer vaccines To understand what are true contraindications for vaccine

More information

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.

More information

Measure Title X RAY PRIOR TO MRI OR CAT SCAN IN THE EVAULATION OF LOWER BACK PAIN Disease State Back pain Indicator Classification Utilization

Measure Title X RAY PRIOR TO MRI OR CAT SCAN IN THE EVAULATION OF LOWER BACK PAIN Disease State Back pain Indicator Classification Utilization Client HMSA: PQSR 2009 Measure Title X RAY PRIOR TO MRI OR CAT SCAN IN THE EVAULATION OF LOWER BACK PAIN Disease State Back pain Indicator Classification Utilization Strength of Recommendation Organizations

More information

Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction

Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction Table of Contents Policy: Commercial Coding Information Information Pertaining

More information

PAEDIATRIC ACUTE CARE GUIDELINE. Varicella. This document should be read in conjunction with this DISCLAIMER

PAEDIATRIC ACUTE CARE GUIDELINE. Varicella. This document should be read in conjunction with this DISCLAIMER Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Varicella Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read in conjunction

More information

July 3, 2015. III. VA policy:

July 3, 2015. III. VA policy: Antiretroviral Postexposure Prophylaxis After Sexual, Injection- Drug Use, or Other Nonoccupational Exposure to HIV (nonoccupational post- exposure prophylaxis [npep]) VA Greater Los Angeles Healthcare

More information

Press release. New England Journal of Medicine publishes phase III study results for RotaTeq, Sanofi Pasteur MSD s rotavirus vaccine in development

Press release. New England Journal of Medicine publishes phase III study results for RotaTeq, Sanofi Pasteur MSD s rotavirus vaccine in development Press release RotaTeq prevented 98% of severe Paediatric Rotavirus Gastroenteritis and reduced related hospitalisation and emergency room visits by almost 96% and 94% respectively New England Journal of

More information

Drug Utilization and Evaluation of Cephalosporin s At Tertiary Care Teaching Hospital, Bangalore

Drug Utilization and Evaluation of Cephalosporin s At Tertiary Care Teaching Hospital, Bangalore Research Article Drug Utilization and Evaluation of Cephalosporin s At Tertiary Care Teaching Hospital, Bangalore HS. Shekar 1*, HR. Chandrashekhar 2, M. Govindaraju 3, P. Venugopalreddy 1, Chikkalingiah

More information

Exposure. What Healthcare Personnel Need to Know

Exposure. What Healthcare Personnel Need to Know Information from the Centers for Disease Control and Prevention National Center for Infectious Diseases Divison of Healthcare Quality Promotion and Division of Viral Hepatitis For additional brochures

More information

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

More information

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) Guidance from the Michigan Department of Health and Human Services Division of Health, Wellness & Disease Control Revised June 2015 The Michigan Department

More information

Hematologic Malignancies/Stem Cell Transplantation Program Clinical Section UCLA Health System Los Angeles, CA 90095

Hematologic Malignancies/Stem Cell Transplantation Program Clinical Section UCLA Health System Los Angeles, CA 90095 Hematologic Malignancies/Stem Cell Transplantation Program Clinical Section UCLA Health System Los Angeles, CA 90095 CS 6.4 DIAGNOSIS AND MANAGEMENT OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE Location:

More information

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

Which injectable medication should I take for relapsing-remitting multiple sclerosis? Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have

More information

Laboratory confirmation requires isolation of Bordetella pertussis or detection of B. pertussis nucleic acid, preferably from a nasopharyngeal swab.

Laboratory confirmation requires isolation of Bordetella pertussis or detection of B. pertussis nucleic acid, preferably from a nasopharyngeal swab. Pertussis Epidemiology in New Zealand New Zealand has continued to experience outbreaks of pertussis in recent decades. This is in part due to historically low immunisation rates and in part because immunity

More information

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline Background... 2 Screening... 2 Recommendations... 2 Ordering and consent... 2 Indications for Periodic HIV Screening...

More information

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes: EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human

More information

Hypotension in Spinal and Epidural Anesthesia. Mansour Hassani Myanroudi, MD* Kamyab Alizadeh, MD** Mojgan Sadeghi, MD***

Hypotension in Spinal and Epidural Anesthesia. Mansour Hassani Myanroudi, MD* Kamyab Alizadeh, MD** Mojgan Sadeghi, MD*** Bahrain Medical Bulletin, Volume 30, No 1, March 2008 Hypotension in Spinal and Epidural Anesthesia Mansour Hassani Myanroudi, MD* Kamyab Alizadeh, MD** Mojgan Sadeghi, MD*** Background: Hypotension occurs

More information

Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs)

Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs) EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products

More information

Memantine (Namenda ) [Developed, April 2010; Revised, March 2012; March 2014] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE

Memantine (Namenda ) [Developed, April 2010; Revised, March 2012; March 2014] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE Memantine (Namenda ) [Developed, April 2010; Revised, March 2012; March 2014] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE Information on indications for use or diagnosis is assumed to be unavailable.

More information

Safety of Antidepressants in Pregnancy and Breastfeeding

Safety of Antidepressants in Pregnancy and Breastfeeding Safety of Antidepressants in Pregnancy and Breastfeeding Exceptional healthcare, personally delivered Background Depression and anxiety disorders are common during pregnancy, affecting nearly one in every

More information

Texas Medicaid/CHIP Vendor Drug Program Drug Utilization Criteria For Outpatient Use Guidelines

Texas Medicaid/CHIP Vendor Drug Program Drug Utilization Criteria For Outpatient Use Guidelines About Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

Pharmacology 260 Online Course Schedule Spring 2012

Pharmacology 260 Online Course Schedule Spring 2012 Pharmacology 260 Online Course Spring 2012 The topics listed below do not necessarily correspond to a 1 - hour lecture period. You should cover the topics for each week at some time during that week. Readings

More information

DATING YOUR GUILD 1952-1960

DATING YOUR GUILD 1952-1960 DATING YOUR GUILD 1952-1960 YEAR APPROXIMATE LAST SERIAL NUMBER PRODUCED 1953 1000-1500 1954 1500-2200 1955 2200-3000 1956 3000-4000 1957 4000-5700 1958 5700-8300 1959 12035 1960-1969 This chart displays

More information

What is the Difference Between HIV and AIDS?

What is the Difference Between HIV and AIDS? What is AIDS? What causes AIDS? AIDS stands for Acquired Immune Deficiency Syndrome. An HIV-positive person receives an AIDS diagnosis after developing one of the CDC-defined AIDS indicator illnesses.

More information

Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment

Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment A WHITE PAPER BY Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment Increased adherence rates deliver improved outcomes for patients FALL 2010 The Benefits of DTM for Rheumatoid Arthritis

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields

More information

Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy

Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy London, UK, 3 February 2011 Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered

More information

CLASS SCHEDULE FOR HEALTH PSYCHOLOGY

CLASS SCHEDULE FOR HEALTH PSYCHOLOGY CLASS SCHEDULE FOR HEALTH PSYCHOLOGY Psychology 1215 (39588) Spring Term, 1999-00 Tue., Thu. 11:00-12:15 314 Bellefield Hall Instructor: Tom Kamarck,Ph.D. Associate Professor, Psychology Office: Bellefield

More information

MAKE ANTIBODIES. Signs & Symptoms of Primary Immune Deficiency

MAKE ANTIBODIES. Signs & Symptoms of Primary Immune Deficiency Signs & Symptoms of Primary Immune Deficiency MAKE ANTIBODIES Dr Jovanka King Department of Allergy & Immunology Women s & Children s Hospital, Adelaide Overview Cook s tour of the immune system Signs

More information

Proposal for deletion Codeine phosphate tablets for pain in children

Proposal for deletion Codeine phosphate tablets for pain in children Introduction Proposal for deletion Codeine phosphate tablets for pain in children Codeine is a phenanthrene opioid derivative. It is listed in the 2010 WHO Model List of Essential Medicines for Children

More information

Results of all scientific investigations with the A.Vogel Sore Throat Spray. Issue 2 - June 2008

Results of all scientific investigations with the A.Vogel Sore Throat Spray. Issue 2 - June 2008 Results of all scientific investigations with the A.Vogel Sore Issue 2 - June 2008 Antiviral Antibacterial Anti-inflammatory Analgetic Immunemodulatory Authors: Andy Suter, Medical Department Roland Schoop,

More information

CIBMTR Infection Data and the New Infection Inserts.

CIBMTR Infection Data and the New Infection Inserts. CIBMTR Infection Data and the New Infection Inserts. Marcie Tomblyn, MD, MS Scientific Director, CIBMTR Infection and Immune Reconstitution Working Committee Overview Indication for expanded data collection

More information

Substance Abuse Treatment. Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence

Substance Abuse Treatment. Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence Spring 2007 Volume 6 Issue 1 ADVISORY News for the Treatment Field Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence What is naltrexone for extendedrelease injectable

More information

Expedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon

Expedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon Expedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon Oregon Health Authority Center for Public Health Practice HIV/STD/TB Section Principles of

More information

Recommendations for Alternative Analgesic and Sedative Agents in the Setting of Drug Shortages

Recommendations for Alternative Analgesic and Sedative Agents in the Setting of Drug Shortages Recommendations for Alternative Analgesic and Sedative Agents in the Setting of Drug Shortages Gail Gesin, PharmD* Clinical Phramacist for Trauma Critical Care Carolinas Medical Center Charlotte, North

More information

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate. EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human

More information

Session 4: The Drug Management Cycle: Selection. David Peters

Session 4: The Drug Management Cycle: Selection. David Peters This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Table 1: Approved Memantine Adult Dosage Recommendations 1-6

Table 1: Approved Memantine Adult Dosage Recommendations 1-6 About Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information

More information

APIC Practice Guidance Committee: Implementation Insights Prevention & Control of Pertussis

APIC Practice Guidance Committee: Implementation Insights Prevention & Control of Pertussis 1275 K Street, NW, Suite 1000 Washington, DC 20005-4006 Phone: 202/789-1890 Fax: 202/789-1899 apicinfo@apic.org www.apic.org APIC Practice Guidance Committee: Implementation Insights Prevention & Control

More information

A Systematic Review of Central Venous Catheter Dressings in Patients Undergoing Hematopoietic Stem Cell Transplantation

A Systematic Review of Central Venous Catheter Dressings in Patients Undergoing Hematopoietic Stem Cell Transplantation A Systematic Review of Central Venous Catheter Dressings in Patients Undergoing Hematopoietic Stem Cell Transplantation Renata Cristina de Campos Pereira Silveira* Karina Dal Sasso Mendes* Cristina Maria

More information

Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria (Review)

Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria (Review) Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria (Review) Omari AAA, Gamble C, Garner P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane

More information

Philadelphia College of Osteopathic Medicine. David A. Smith Philadelphia College of Osteopathic Medicine,

Philadelphia College of Osteopathic Medicine. David A. Smith Philadelphia College of Osteopathic Medicine, Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is 5% Imiquimod Cream More Efficacious

More information

Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion

Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment

More information

- 301-17. SICKLE CELL SCREENING AND SELECT TOPICS IN PREVENTION OF COMPLICATIONS Mark Schuster, M.D., Ph.D.

- 301-17. SICKLE CELL SCREENING AND SELECT TOPICS IN PREVENTION OF COMPLICATIONS Mark Schuster, M.D., Ph.D. - 301-17. SICKLE CELL SCREENING AND SELECT TOPICS IN PREVENTION OF COMPLICATIONS Mark Schuster, M.D., Ph.D. We used the following sources to construct indicators for sickle cell disease screening for newborns

More information

Antibiotic Prophylaxis for the Prevention of Infective Endocarditis and Prosthetic Joint Infections for Dentists

Antibiotic Prophylaxis for the Prevention of Infective Endocarditis and Prosthetic Joint Infections for Dentists PRACTICE ADVISORY SERVICE FAQ 6 Crescent Road, Toronto, ON Canada M4W 1T1 T: 416.961.6555 F: 416.961.5814 Toll Free: 1.800.565.4591 www.rcdso.org Antibiotic Prophylaxis for the Prevention of Infective

More information

Sore throat. Infection. Fungi: Viruses: Bacteria:

Sore throat. Infection. Fungi: Viruses: Bacteria: Sore throat Infection Infection is an illness that is caused by germs or micro-organisms (tiny organisms) that invade the body. Micro-organisms include the like of viruses, bacteria and fungi.1 Bacteria:

More information

Pre-exposure prophylaxis (PrEP)

Pre-exposure prophylaxis (PrEP) FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.

More information

B I N G O B I N G O. Hf Cd Na Nb Lr. I Fl Fr Mo Si. Ho Bi Ce Eu Ac. Md Co P Pa Tc. Uut Rh K N. Sb At Md H. Bh Cm H Bi Es. Mo Uus Lu P F.

B I N G O B I N G O. Hf Cd Na Nb Lr. I Fl Fr Mo Si. Ho Bi Ce Eu Ac. Md Co P Pa Tc. Uut Rh K N. Sb At Md H. Bh Cm H Bi Es. Mo Uus Lu P F. Hf Cd Na Nb Lr Ho Bi Ce u Ac I Fl Fr Mo i Md Co P Pa Tc Uut Rh K N Dy Cl N Am b At Md H Y Bh Cm H Bi s Mo Uus Lu P F Cu Ar Ag Mg K Thomas Jefferson National Accelerator Facility - Office of cience ducation

More information

Program Approved by AoA, NCOA. Website: www.homemeds.org

Program Approved by AoA, NCOA. Website: www.homemeds.org MEDICATION MANAGEMENT IMPROVEMENT SYSTEM: HomeMeds SM The HomeMeds SM system is a collaborative approach to identifying, assessing, and resolving medication problems in community-dwelling older adults.

More information

Health Benchmarks Program Clinical Quality Indicator Specification 2013

Health Benchmarks Program Clinical Quality Indicator Specification 2013 Health Benchmarks Program Clinical Quality Indicator Specification 2013 Measure Title USE OF IMAGING STUDIES FOR LOW BACK PAIN Disease State Musculoskeletal Indicator Classification Utilization Strength

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

Indicated for flu treatment for ages 2 weeks and older

Indicated for flu treatment for ages 2 weeks and older DOSAGE AND ADMINISTRATION IN ADULT AND PEDIATRIC PATIENTS Please see Important Safety Information on pages 6 8. Indicated for flu treatment for ages 2 weeks and older Available in 30-mg, 45-mg, and 75-mg

More information

Maj Alison Baum. R3, Nellis FMR

Maj Alison Baum. R3, Nellis FMR Maj Alison Baum R3, Nellis FMR What are some of your thoughts about birth plans? http://www.youtube.com/watch?v=hh62v0c xf04 Labor: Pain management wishes Doulas Episiotomy Intermittent fetal monitoring

More information

The timing of vaccination with respect to anaesthesia and surgery. 1. Surgery following immunisation with inactivated vaccines

The timing of vaccination with respect to anaesthesia and surgery. 1. Surgery following immunisation with inactivated vaccines The timing of vaccination with respect to anaesthesia and surgery Main recommendations: 1. Surgery following immunisation with inactivated vaccines Delay surgery 48 hours post vaccination to avoid postvaccination

More information

Management of HIV and TB Co-infection in South Africa

Management of HIV and TB Co-infection in South Africa Management of HIV and TB Co-infection in South Africa Halima Dawood Department of Medicine Case Report 39 yr old female Referred to clinic on 14/06/2006 for consideration to commence antiretroviral therapy

More information